The role of these genes in the immunotherapy queue was analysed, and the results show that PSMB8/PSMB9/PSMB10/PSME1/PSME2/IRF1 in multiple clinical response immune checkpoint inhibitor treatment group had expressed, in the stable group of disease, the low expression of queue these solid tumours including lung cancer, kidney cancer, bladder cancer, detailed gap analysis statistical data as shown in Tables 1–5. Here, PSME1 is linked to urinary bladder carcinoma.